Press Archive
A new survey published in the Journal of Drugs in Dermatology identifies several barriers that prevent the consistent use of fungal diagnostic preparations to correctly identify cutaneous fungal infections.
The GW Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma. The study is led by Vishal A. Patel, MD, FAAD, FACMS, director of the Cutaneous Oncology Program at the GW Cancer Center.
The GW is pleased to announce that the GW Biorepository is now a core facility. Housed at the GW School of Medicine and Health Sciences, the GW Biorepository received designation as a shared resource available to all GW investigators and is accredited by the College of American Pathologists…
Ali Ahmed, MD, MPH, professor of medicine, was the senior author and Richard M. Allman, MD, clinical professor of medicine, was a co-author on a paper that found stopping digoxin in some patients with heart failure is linked to higher risk of death and hospital readmission.
A research team led by Yanfen Hu, PhD, is studying the role of the tumor suppressor BRCA1 in the homologous recombination pathway of DNA double-strand break repair.
Steven Davis, MD, was recognized as the 2019 National Clerkship Director of the Year at the Society for Academic Emergency Medicine.
Researchers at the GW Cancer Center found that sun safety practices for attendees at skin cancer screening events differ from the general public.
Researchers in the GW Department of Dermatology found that collagen powder is just as effective in managing skin biopsy wounds as primary closure with non-absorbable sutures.
A new study published in the Journal of Investigative Medicine has found that the SMHS Clinical and Translational Research Scholarly Concentration is effective in training physician-researchers.
Hoth Therapeutics, Inc. has entered into a sponsored research agreement with GW to explore the potential use of Aprepitant for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients.